Literature DB >> 35427257

Pharmacologic Mydriasis Secondary to Topical Glycopyrronium Tosylate Cloths: Clinical Characterization From a Multicenter Analysis.

Aaron R Kaufman1, Shawn Gulati, John H Pula, Timothy M Janetos, Neena R Cherayil, Eric Chiu, Emily Anne Shepherd, Karl C Golnik, Enrique Garcia-Valenzuela, Peter W MacIntosh, Brooke T Johnson, Kimberlee M Curnyn.   

Abstract

BACKGROUND: Topical glycopyrronium tosylate (GT) is an anticholinergic medication for treatment of axillary hyperhidrosis. Pharmacologic mydriasis and anisocoria from topical GT has been reported and may be underrecognized. This study aims to clinically characterize patients presenting with pharmacologic mydriasis from exposure to this medication.
METHODS: This study is a retrospective observational case series. A multicenter chart review of 16 patients diagnosed with pharmacologic mydriasis secondary to topical GT was performed.
RESULTS: Eight patients (50.0%) were age 18 years and younger, and 14 patients (87.5%) were female. Unilateral mydriasis (anisocoria) occurred in 14 patients (87.5%). Fourteen patients (87.5%) did not initially volunteer topical GT as a "medication," and the history of topical GT exposure needed to be elicited with further questioning. Hand hygiene details were known for 12 patients, and all reported that they did not wash their hands after GT application. Six patients (37.5%) were soft contact lens users. One patient had possible exposure through a family member's use of the medication. Ocular symptoms were common (blurry vision [11 patients, 68.8%] and eye dryness [7 patients, 43.8%]), but systemic anticholinergic symptoms were uncommon (such as constipation [1 patient, 6.3%] and urinary symptoms [3 patients, 18.8%]).
CONCLUSIONS: Mydriasis associated with topical GT seems to be a consequence of local exposure rather than systemic toxicity. Because patients may not volunteer topical GT as a medication, eliciting a history of exposure often requires further specific questioning. Soft contact lens wear and poor postapplication hand hygiene seem to be associated with mydriasis in GT use.
Copyright © 2022 by North American Neuro-Ophthalmology Society.

Entities:  

Year:  2022        PMID: 35427257      PMCID: PMC9508283          DOI: 10.1097/WNO.0000000000001567

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   4.415


  16 in total

1.  Anisocoria? Don't sweat it: Wipes for excessive perspiration might cause mydriasis.

Authors:  Majid Moshirfar; MacGregor N Hall; William B West; Shannon E McCabe
Journal:  J Cataract Refract Surg       Date:  2021-05-01       Impact factor: 3.351

Review 2.  The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up.

Authors:  Shiri Nawrocki; Jisun Cha
Journal:  J Am Acad Dermatol       Date:  2019-01-31       Impact factor: 11.527

3.  Don't Sweat the Blown Pupil: Anisocoria in Patients Using Qbrexza.

Authors:  Shaza N Al-Holou; Stephen N Lipsky; Barry N Wasserman
Journal:  Ophthalmology       Date:  2020-10       Impact factor: 12.079

4.  Use of gloves when applying topical glycopyrronium for treatment of primary axillary hyperhidrosis.

Authors:  Spyros M Siscos; Karen Figenshau; Anand Rajpara
Journal:  J Am Acad Dermatol       Date:  2019-12-14       Impact factor: 11.527

5.  Reversible anisocoria due to inadvertent ocular exposure to topical anticholinergic treatment for primary axillary hyperhidrosis.

Authors:  Aryan Pashaei-Marandi; Jed H Assam; Anthony Arnold; Andrew G Lee; Laura Bonelli
Journal:  Can J Ophthalmol       Date:  2019-06-04       Impact factor: 1.882

Review 6.  Pharmacology, toxicology and clinical safety of glycopyrrolate.

Authors:  Monika Chabicovsky; Swantje Winkler; Michael Soeberdt; Ana Kilic; Clarissa Masur; Christoph Abels
Journal:  Toxicol Appl Pharmacol       Date:  2019-03-21       Impact factor: 4.219

7.  Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.

Authors:  Dee Anna Glaser; Adelaide A Hebert; Alexander Nast; William P Werschler; Lawrence Green; Richard Mamelok; Janice Drew; John Quiring; David M Pariser
Journal:  J Am Acad Dermatol       Date:  2018-07-10       Impact factor: 11.527

8.  A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.

Authors:  Dee Anna Glaser; Adelaide A Hebert; Alexander Nast; William P Werschler; Lawrence Green; Richard D Mamelok; John Quiring; Janice Drew; David M Pariser
Journal:  Am J Clin Dermatol       Date:  2019-08       Impact factor: 7.403

9.  Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.

Authors:  Adelaide A Hebert; Dee Anna Glaser; Lawrence Green; Cheryl Hull; Jennifer Cather; Janice Drew; Ramanan Gopalan; David M Pariser
Journal:  Pediatr Dermatol       Date:  2020-03-08       Impact factor: 1.588

10.  Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.

Authors:  David M Pariser; Adelaide A Hebert; Janice Drew; John Quiring; Ramanan Gopalan; Dee Anna Glaser
Journal:  Am J Clin Dermatol       Date:  2019-02       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.